Skip to main content
Premium Trial:

Request an Annual Quote

Bioke to Distribute BioSkryb Genomic Amplification Tech in Europe

NEW YORK — Dutch cell signaling technology company Bioke said on Tuesday that it has signed an agreement to distribute BioSkryb Genomics' genomic amplification technology in several European nations.

Under the terms of the deal, Bioke will offer BioSkryb products based on the company's primary template-directed amplification (PTA) technology in the Netherlands, Belgium, and Luxembourg, as well as Denmark, Norway, Sweden, and Finland.

Products covered under the deal include ResolveDNA for single-cell whole-genome reproduction and the ResolveOme system for whole-genome and whole-transcriptome analysis in individual cells. BioSkryb licensed the PTA technology from St. Jude Children's Research Hospital in mid-2020.

Financial and other terms of the arrangement were not disclosed.

"By combining Bioke's in-depth knowledge of the genomics market space with BioSkryb's innovative [whole-genome amplification] approach, this agreement will provide tools to researchers to study genomic heterogeneity and enable the development of new diagnostics for insights into human disease at the cellular level," Robert Hovingh, Bioke's sales manager for Europe, said in a statement.

In late 2022, Durham, North Carolina-based BioSkryb licensed ResolveDNA to CooperSurgical for commercialization in the women's reproductive health market.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.